JP Morgan Chase
KRYS icon

JP Morgan Chase’s Krystal Biotech KRYS Stock Holding History

JP Morgan Chase’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,500
Closed -$2.21M – 7608
2025
Q3 		$2.21M Buy
+12,500
New +$1.87M ﹤0.01% 4011
2024
Q2 		– Sell
-300
Closed -$53.4K – 7582
2024
Q1 		$53.4K Buy
+300
New +$41.7K ﹤0.01% 5919

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase's KRYS Position: Q2 2026 in Review

JP Morgan Chase reduced its Krystal Biotech (KRYS) stake by 12% in Q2 2026, selling an estimated $3.51M and leaving 87,342 shares worth $33.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1790.

JP Morgan Chase first reported a position in KRYS in Q2 2018 and has held it in 33 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • JP Morgan Chase held 87,342 shares of Krystal Biotech worth $33.5M as of Q2 2026.
  • JP Morgan Chase sold 11,763 Krystal Biotech shares in Q2 2026, an estimated $3.51M.
  • Krystal Biotech made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #1790 holding.
  • JP Morgan Chase first reported a position in Krystal Biotech in Q2 2018 and has held it in 33 quarters since.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.